Shares of Surgery Partners surged 7.5% to $14.98 after a regulatory filing revealed that Jupiter Topco — an entity linked to major institutional capital — had amassed 13.9 million shares, a 10.6% stake worth roughly $233 million. The disclosure, coming on the heels of a quarterly earnings beat, raises a pointed question: is this the inflection point for a stock that has lost nearly half its value over the past year? A $233 Million Outsider Bet Lifts Surgery Partners — But Does the Company's Shaky Balance Sheet Deserve the Vote of Confidence?
Shares of Surgery Partners jumped 7.5% to $14.98 after a regulatory filing revealed Jupiter Topco — a large institutional investor that has been building sizable new positions across healthcare and industrial names — disclosed ownership of 13.9 million shares, a 10.6% stake valued at roughly $233 million. The disclosure lands just weeks after the company posted a better-than-expected quarter, making it the clearest single catalyst in an otherwise volatile stretch for the stock.
An Earnings Beat Provided the Opening, but the Numbers Tell a Mixed Story. Surgery Partners reported Q2 revenue of $848.9 million, up 2.7% year over year, with same-facility revenue up 5.0% driven by a 4.8% increase in revenue per surgical case.
Non-GAAP earnings of $0.10 per share beat the consensus estimate of $0.07 by roughly 49%. Yet the headline obscures real weakness: adjusted EBITDA (a common measure of operating profit before certain costs) fell to $125.2 million from $129.0 million, and the company's net loss widened to $15.0 million from $2.5 million a year ago. The beat was real, but the underlying profitability trend is heading the wrong direction.
A Big New Shareholder Sends a Signal — at a Deep Discount. Jupiter Topco's stake was accumulated at prices well below the average analyst target of $18.64, where Surgery Partners was recently heading into earnings. That gap suggests the buyer sees meaningful upside. Notably, director Teresa Deluca also purchased 10,000 shares on August 18 at $14.35 — a rare insider buy after 12 insider transactions in six months, all of which were sales. Two independent bets at these levels signal conviction that the stock is cheap.
Heavy Debt and Sluggish Growth Remain the Core Risks. Surgery Partners ended Q2 with net debt running roughly 4.4 times its annual EBITDA — a high leverage ratio meaning the company owes about four and a half years' worth of operating profits.
Management reaffirmed full-year revenue guidance of $3.35–$3.45 billion and EBITDA of at least $530 million , but operating margins contracted 2.4 percentage points year over year, showing expenses are growing faster than revenue.
The Bottom Line for Shareholders. A 10.6% stake from a well-capitalized outsider and a director's open-market buy create a credibility floor beneath the stock. But Surgery Partners still needs to prove it can convert rising revenue into actual profits — not just smaller-than-feared losses — before today's rally becomes a sustainable re-pricing.